Taysha Regains Full Rights to TSHA-102 Program

Taysha Gene Therapies ( (TSHA) ) has provided an announcement.

On October 16, 2025, Taysha Gene Therapies announced it has regained full rights to its lead TSHA-102 program for Rett syndrome after the expiration of a 2022 Option Agreement with Astellas. This development allows Taysha strategic flexibility to advance the program, which has shown promising safety and efficacy data, received FDA Breakthrough Therapy designation, and is poised for a pivotal trial this quarter, highlighting a significant market opportunity given the unmet medical need in Rett syndrome.

The most recent analyst rating on (TSHA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Taysha Gene Therapies stock, see the TSHA Stock Forecast page.

Spark’s Take on TSHA Stock

According to Spark, TipRanks’ AI Analyst, TSHA is a Neutral.

Taysha Gene Therapies’ stock score is primarily influenced by its challenging financial performance, despite strong technical momentum and positive earnings call highlights. The company’s ongoing financial losses and cash flow issues weigh heavily on the score, though clinical progress and regulatory achievements provide a positive outlook.

To see Spark’s full report on TSHA stock, click here.

More about Taysha Gene Therapies

Taysha Gene Therapies is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies. The company aims to address severe unmet medical needs and improve the lives of patients and caregivers.

Average Trading Volume: 5,860,173

Technical Sentiment Signal: Buy

Current Market Cap: $1.46B

See more data about TSHA stock on TipRanks’ Stock Analysis page.